{
    "pmcid": "10588750",
    "qa_pairs": {
        "What is the primary target for the nanobody screening in the study on SARS-CoV-2 nanobody binders?": [
            "The S1 subunit of the SARS-CoV-2 spike protein, particularly the receptor-binding domain (RBD).",
            "The N-terminal domain of the SARS-CoV-2 spike protein.",
            "The S2 subunit of the SARS-CoV-2 spike protein.",
            "The nucleocapsid protein of SARS-CoV-2."
        ],
        "What mutations were analyzed to confirm the importance of residues in maintaining binding and neutralization efficacy?": [
            "Mutations in Nb-H6 (N72A and R97A) and RBD (Y489A and Y499A)",
            "Mutations in Nb-H6 (N72A and R97A) and RBD (Y453A and Y501A)",
            "Mutations in Nb-H6 (N72A and R97A) and RBD (Y456A and Y484A)",
            "Mutations in Nb-H6 (N72A and R97A) and RBD (Y452A and Y490A)"
        ],
        "What specific residues on the RBD does Nb-H6 bind to, according to structural modeling and docking studies?": [
            "Tyr449 and Tyr489",
            "Tyr453 and Tyr501",
            "Tyr456 and Tyr484",
            "Tyr452 and Tyr490"
        ],
        "What type of library was used to screen for nanobodies against the SARS-CoV-2 S1 protein?": [
            "A na\u00efve phage display library",
            "An immune phage display library",
            "A synthetic antibody library",
            "A yeast display library"
        ],
        "Which nanobody was characterized for its neutralizing activity against SARS-CoV-2 and its variants in the study?": [
            "Nb-H6",
            "Nb-C7",
            "Nb-D4",
            "Nb-F9"
        ]
    }
}